-
1
-
-
33846006173
-
The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
-
(2006)
Lancet
, vol.368
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
2
-
-
33847685714
-
Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus
-
DOI 10.1097/MED.0b013e3280a02f65, PII 0126602920070400000003
-
Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007;14:98-107 (Pubitemid 46363290)
-
(2007)
Current Opinion in Endocrinology, Diabetes and Obesity
, vol.14
, Issue.2
, pp. 98-107
-
-
Rosenstock, J.1
Zinman, B.2
-
3
-
-
22744449063
-
Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
-
DOI 10.1021/jm050261p
-
Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:5025-5037 (Pubitemid 41033142)
-
(2005)
Journal of Medicinal Chemistry
, vol.48
, Issue.15
, pp. 5025-5037
-
-
Augeri, D.J.1
Robl, J.A.2
Betebenner, D.A.3
Magnin, D.R.4
Khanna, A.5
Robertson, J.G.6
Wang, A.7
Simpkins, L.M.8
Taunk, P.9
Huang, Q.10
Han, S.-P.11
Abboa-Offei, B.12
Cap, M.13
Xin, L.14
Tao, L.15
Tozzo, E.16
Welzel, G.E.17
Egan, D.M.18
Marcinkeviciene, J.19
Chang, S.Y.20
Biller, S.A.21
Kirby, M.S.22
Parker, R.A.23
Hamann, L.G.24
more..
-
4
-
-
34248223285
-
Biology of incretins: GLP-1 and GIP
-
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157
-
(2007)
Gastroenterology
, vol.132
, pp. 2131-2157
-
-
Baggio, L.L.1
Drucker, D.J.2
-
5
-
-
0037342614
-
Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats
-
DOI 10.2337/diabetes.52.3.741
-
Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003;52:741-750 (Pubitemid 36323582)
-
(2003)
Diabetes
, vol.52
, Issue.3
, pp. 741-750
-
-
Pospisilik, J.A.1
Martin, J.2
Doty, T.3
Ehses, J.A.4
Pamir, N.5
Lynn, F.C.6
Piteau, S.7
Demuth, H.-U.8
McIntosh, C.H.S.9
Pederson, R.A.10
-
6
-
-
33644618433
-
The biology of incretin hormones
-
Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-165
-
(2006)
Cell Metab
, vol.3
, pp. 153-165
-
-
Drucker, D.J.1
-
7
-
-
34247357752
-
Oral antidiabetic agents in type 2 diabetes
-
DOI 10.1185/030079907X178766
-
Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin 2007;23:945-952 (Pubitemid 46631497)
-
(2007)
Current Medical Research and Opinion
, vol.23
, Issue.4
, pp. 945-952
-
-
Levetan, C.1
-
8
-
-
42149194313
-
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
-
Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-386
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 376-386
-
-
Rosenstock, J.1
Sankoh, S.2
List, J.F.3
-
9
-
-
0021813187
-
Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
-
DOI 10.1007/BF00280883
-
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419 (Pubitemid 15018832)
-
(1985)
Diabetologia
, vol.28
, Issue.7
, pp. 412-419
-
-
Matthews, D.R.1
Hosker, J.P.2
Rudenski, A.S.3
-
10
-
-
0032821965
-
Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp
-
DOI 10.2337/diacare.22.9.1462
-
Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470 (Pubitemid 29418240)
-
(1999)
Diabetes Care
, vol.22
, Issue.9
, pp. 1462-1470
-
-
Matsuda, M.1
Defronzo, R.A.2
-
11
-
-
0035089445
-
A model-based method for assessing insulin sensitivity from the oral glucose tolerance test
-
Mari A, Pacini G, Murphy E, et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001;24:539-548 (Pubitemid 32198427)
-
(2001)
Diabetes Care
, vol.24
, Issue.3
, pp. 539-548
-
-
Mari, A.1
Pacini, G.2
Murphy, E.3
Ludvik, B.4
Nolan, J.J.5
-
12
-
-
48149095259
-
Translating the A1C assay into estimated average glucose values
-
Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478
-
(2008)
Diabetes Care
, vol.31
, pp. 1473-1478
-
-
Nathan, D.M.1
Kuenen, J.2
Borg, R.3
-
13
-
-
33845472504
-
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
-
DOI 10.2337/dc06-0703
-
Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-2637 (Pubitemid 44912190)
-
(2006)
Diabetes Care
, vol.29
, Issue.12
, pp. 2632-2637
-
-
Aschner, P.1
Kipnes, M.S.2
Lunceford, J.K.3
Sanchez, M.4
Mickel, C.5
Williams-Herman, D.E.6
-
14
-
-
55449096196
-
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: A model-based approach
-
Xu L, Man CD, Charbonnel B, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008;10:1212-1220
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 1212-1220
-
-
Xu, L.1
Man, C.D.2
Charbonnel, B.3
-
15
-
-
52249090472
-
Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: Analysis of pooled vildagliptin monotherapy database
-
Pratley RE, Schweizer A, Rosenstock J, et al. Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008;10:931-938
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 931-938
-
-
Pratley, R.E.1
Schweizer, A.2
Rosenstock, J.3
|